UGANDA-IMMIGRATION
When it comes to Uganda, travelers will immediately remember a vast expanse of savannah across the country, a diverse ethnic culture, and a wealth of wildlife. Besides safari tours, most international travelers also visit this beautiful country to discover the diverse culture in Uganda.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220618005004/en/
The culture of Uganda and its age-old tradition attract many foreign tourists
Uganda tourism statistics show a gradual increase in the number of tourists to Uganda in 2021. Thanks to the reopening of tourism, Uganda is expected to welcome more international travelers in 2022.
The culture of Uganda is made up of more than 50 tribes, including Ugandan indigenous people, and a small population migrated from Europeans, Asians, and Arabians. There are four main ethnic groups in Uganda, including the Bantu, the Nilotics, the NiloHamitics, and the Hamites.
The importance of culture in Uganda has been recognized through the cultural values it brings to the community. In this diverse culture, the traditional dance has always been a part of Uganda's identity. Each ethnic community has distinctive dances with different meanings and purposes, making it easy for visitors to distinguish between the tribes. Local people often integrate these dances into their day-to-day life to keep and share cultural values with different generations.
The "Gomesi" and the "Kanzu" are traditional costumes in Uganda. The "Gomesi" is a national dress in Uganda that Ugandan women often wear at events or ceremonies, while "Kanzu" is worn by Ugandan men during cultural functions.
Some cultural sites for travelers to immerse in cultures and traditions in Uganda
The best way for travelers to understand the diversity of new cultures and traditions in Uganda is to interact with the local community.
Going off-the-beaten-path in Karamoja village, travelers can discover the unique culture of the local people through their dress code, traditional dances, and local crafts. Karamojong people are mainly semi-nomadic pastoralists living in the North Eastern region of Uganda for hundreds of years.
The Ndere Cultural Center is set up with the primary purpose of maintaining Uganda's culture alive. This Center is an ideal destination for travelers to understand different cultures in Uganda . They can enjoy the cultural song and dance performances with handmade instruments from various tribes in Uganda.
Before departing, travelers should consider purchasing travel insurance that will help them cover their medical expenses should things go wrong and provide them additional benefits on their cultural tours in Uganda.
Uganda Immigration Services recommends tourists to apply for Uganda e Visa online beforehand
Travelers should keep in mind that they need to get a visa to enter Uganda. The fastest and most convenient way to obtain a visa is to apply for Uganda e Visa online .
“I had difficulty applying for a Uganda e-Visa on the Government website. Fortunately, experts from Uganda Immigration Services have helped me simplify the e-Visa application process, so I can obtain an e-Visa easier at a reasonable Uganda visa fee. I was definitely impressed with their enthusiasm and professionalism.”, said Key Smith.
Experts from Uganda Immigration Services also suggest that travelers should check Uganda visa requirements so that their visa application will be processed faster without interruption.
Uganda Immigration Services provides customers the comprehensive service of e-visa, travel insurance, sim card, and car pick up. From now on, travelers can expect to get an e-visa to the Pearl of Africa easier than ever before.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220618005004/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom